Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has been featured in an editorial published by AINewsWire, part of the Dynamic Brand Portfolio @IBN, highlighting the growing role of artificial intelligence in transforming pharmaceutical manufacturing and regulatory compliance. The article outlines a shift from traditional audit-based systems to real-time, AI-driven monitoring that continuously validates and optimizes production processes in alignment with evolving Good Manufacturing Practice standards, positioning companies like Oncotelic at the intersection of life sciences and advanced digital technologies.
The editorial underscores how AI is enabling pharmaceutical companies to move beyond periodic audits toward continuous, real-time oversight. This approach leverages machine learning and data analytics to monitor production lines, detect anomalies, and ensure compliance with regulatory standards more efficiently. For Oncotelic, a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, the integration of AI into manufacturing could accelerate drug development and improve quality control, particularly for its late-stage therapeutic candidates targeting high-unmet-need cancers and rare pediatric indications.
Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. The company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership, which is advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology and rare disease therapeutics.
The full press release can be viewed at https://ibn.fm/HyPYp. For the latest news and updates relating to OTLC, visit the company’s newsroom at https://ibn.fm/OTLC.
AINewsWire is a specialized communications platform focusing on the latest advancements in artificial intelligence. It is one of over 75 brands within the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions, article syndication, press release enhancement, social media distribution, and corporate communications solutions. With a seasoned team of contributing journalists and writers, AINW aims to serve private and public companies seeking to reach a wide audience of investors, influencers, consumers, journalists, and the general public.
